Insulin-resistance and benign prostatic hyperplasia: the connection
- PMID: 20553919
- DOI: 10.1016/j.ejphar.2010.05.042
Insulin-resistance and benign prostatic hyperplasia: the connection
Abstract
Benign prostatic hyperplasia (BPH) is a highly prevalent disease in the aged men population characterized by augmented cell proliferation and contractility of the prostate gland. Prior studies have demonstrated the relationship between BPH and insulin-resistance syndrome. During insulin-resistance, hyperinsulinemia develops to combat the decreased responsiveness of the body towards insulin. Although, the compensatory hyperinsulinemia prevents development of fasting hyperglycemia in insulin-resistant individuals, the increased level of circulating insulin directly and/or indirectly affects different molecular signaling and can promote prostatic growth. Insulin-resistance syndrome includes group of disorders, such as obesity, dyslipidemia, sympathetic overactivity, hyperinsulinemia and each individually reported as risk factor for the development of BPH. The present review describes the inter-relationships between different insulin-resistance associated factors and their possible involvement in the pathogenesis of BPH.
Copyright (c) 2010 Elsevier B.V. All rights reserved.
Similar articles
-
Increased cell proliferation and contractility of prostate in insulin resistant rats: linking hyperinsulinemia with benign prostate hyperplasia.Prostate. 2010 Jan 1;70(1):79-89. doi: 10.1002/pros.21041. Prostate. 2010. PMID: 19790233
-
Hyperinsulinemia and dyslipidemia in non-diabetic benign prostatic hyperplasia.Clin Chim Acta. 2006 Aug;370(1-2):89-93. doi: 10.1016/j.cca.2006.01.019. Epub 2006 Mar 3. Clin Chim Acta. 2006. PMID: 16516184
-
Calculated fast-growing benign prostatic hyperplasia--a risk factor for developing clinical prostate cancer.Scand J Urol Nephrol. 2002;36(5):330-8. doi: 10.1080/003655902320783827. Scand J Urol Nephrol. 2002. PMID: 12487736
-
Insulin resistance, the insulin resistance syndrome, and cardiovascular disease.Panminerva Med. 2005 Dec;47(4):201-10. Panminerva Med. 2005. PMID: 16489319 Review.
-
Obesity and benign prostatic hyperplasia: clinical connections, emerging etiological paradigms and future directions.J Urol. 2009 Dec;182(6 Suppl):S27-31. doi: 10.1016/j.juro.2009.07.086. J Urol. 2009. PMID: 19846130 Review.
Cited by
-
Diet-Induced Hyperinsulinemia as a Key Factor in the Etiology of Both Benign Prostatic Hyperplasia and Essential Hypertension?Nutr Metab Insights. 2018 May 8;11:1178638818773072. doi: 10.1177/1178638818773072. eCollection 2018. Nutr Metab Insights. 2018. PMID: 30455570 Free PMC article. Review.
-
Metabolic syndrome does not impair the response to alfuzosin treatment in men with lower urinary tract symptoms: a double-blind, randomized, placebo-controlled study.Turk J Urol. 2015 Sep;41(3):125-31. doi: 10.5152/tud.2015.89656. Turk J Urol. 2015. PMID: 26516595 Free PMC article.
-
Benign prostatic hyperplasia: a new metabolic disease of the aging male and its correlation with sexual dysfunctions.Int J Endocrinol. 2014;2014:329456. doi: 10.1155/2014/329456. Epub 2014 Feb 13. Int J Endocrinol. 2014. PMID: 24688539 Free PMC article. Review.
-
Glycemic control and prostate antigen levels in individuals with diabetes based on NHANES data.Sci Rep. 2025 May 6;15(1):15828. doi: 10.1038/s41598-025-00853-2. Sci Rep. 2025. PMID: 40328819 Free PMC article.
-
Urological aspects of the metabolic syndrome.Nat Rev Urol. 2011 Aug 2;8(9):483-94. doi: 10.1038/nrurol.2011.112. Nat Rev Urol. 2011. PMID: 21811224 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical